These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 30660493)

  • 21. Ipsilateral hemigland prostate biopsy may underestimate cancer burden in patients with unilateral mpMRI-visible lesions.
    Phelps TE; Yilmaz EC; Harmon SA; Belue MJ; Shih JH; Garcia C; Hazen LA; Toubaji A; Merino MJ; Gurram S; Choyke PL; Wood BJ; Pinto PA; Turkbey B
    Abdom Radiol (NY); 2023 Mar; 48(3):1079-1089. PubMed ID: 36526922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. How Often Does Magnetic Resonance Imaging Detect Prostate Cancer Missed by Transrectal Ultrasound?
    Herlemann A; Overland MR; Washington SL; Cowan JE; Westphalen AC; Carroll PR; Nguyen HG; Shinohara K; Cooperberg MR
    Eur Urol Focus; 2021 Nov; 7(6):1268-1273. PubMed ID: 32868222
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Targeted Multiparametric Magnetic Resonance Imaging/Ultrasound Fusion Biopsy for Quantitative Gleason 4 Grading Prediction in Radical Prostatectomy Specimens: Implications for Active Surveillance Candidate Selection.
    Kachanov M; Budäus L; Beyersdorff D; Karakiewicz PI; Tian Z; Falkenbach F; Tilki D; Maurer T; Sauter G; Graefen M; Leyh-Bannurah SR
    Eur Urol Focus; 2023 Mar; 9(2):303-308. PubMed ID: 36184537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    Chaloupka M; Pyrgidis N; Ebner B; Volz Y; Pfitzinger PL; Berg E; Enzinger B; Atzler M; Ivanova T; Clevert DA; Buchner A; Stief CG; Apfelbeck M
    BJU Int; 2024 May; 133(5):548-554. PubMed ID: 38060339
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer upgrading with serial prostate magnetic resonance imaging and repeat biopsy in men on active surveillance: are confirmatory biopsies still necessary?
    Osses DF; Drost FH; Verbeek JFM; Luiting HB; van Leenders GJLH; Bangma CH; Krestin GP; Roobol MJ; Schoots IG
    BJU Int; 2020 Jul; 126(1):124-132. PubMed ID: 32232921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging.
    Chaloupka M; Bischoff R; Pfitzinger P; Lellig E; Ledderose S; Buchner A; Schlenker B; Stief C; Clevert DA; Apfelbeck M
    Clin Hemorheol Microcirc; 2019; 73(1):105-111. PubMed ID: 31561351
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database.
    Barletta F; Mazzone E; Stabile A; Scuderi S; Brembilla G; de Angelis M; Cirulli GO; Cucchiara V; Gandaglia G; Karnes RJ; Roupret M; De Cobelli F; Montorsi F; Briganti A
    World J Urol; 2022 Nov; 40(11):2683-2688. PubMed ID: 36149448
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Biopsy With Reduced Number of Cores: Optimal Sampling Scheme in Patients Undergoing Magnetic Resonance Imaging/Transrectal Ultrasound Fusion Prostate Biopsy.
    Shen WW; Cui LG; Ran WQ; Sun Y; Jiang J; Pei XL; Chen W
    Ultrasound Med Biol; 2020 May; 46(5):1197-1207. PubMed ID: 32107089
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer.
    Leyh-Bannurah SR; Kachanov M; Karakiewicz PI; Beyersdorff D; Pompe RS; Oh-Hohenhorst SJ; Fisch M; Maurer T; Graefen M; Budäus L
    World J Urol; 2021 Jan; 39(1):81-88. PubMed ID: 32248363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of multiparametric MRI- and microultrasound-targeted biopsy in biopsy-naïve patients with a PI-RADS 5 lesion: a single-institutional study.
    Avolio PP; Fasulo V; Sanchez-Salas R; Maffei D; Frego N; Lazzeri M; Paciotti M; Saita A; Hurle R; Guazzoni G; Casale P; Buffi NM; Lughezzani G
    World J Urol; 2023 Sep; 41(9):2335-2342. PubMed ID: 37418017
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of the optimal strategy in men with a single unilateral suspicious lesion on MRI undergoing transperineal MRI/ultrasound fusion prostate biopsy.
    Yusim I; Mazor E; Frumkin E; Jabareen M; Hefer B; Elsaraya N; Li S; Rouvinov K; Novack V; Mabjeesh NJ
    Prostate; 2023 Sep; 83(13):1255-1262. PubMed ID: 37263774
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Gleason Grade Group Concordance between Systematic Template Combining Magnetic Resonance Imaging Fusion Targeted Biopsy and Radical Prostatectomy Specimens: A Comparison of Transperineal and Transrectal Approaches.
    Wu S; Feldman AS; Kim MM; Lin SX; Cornejo KM; Harisinghani MG; Dahl DM; Wu CL
    Urology; 2023 May; 175():151-156. PubMed ID: 36828261
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transperineal multiparametric magnetic resonance imaging-ultrasound fusion-targeted prostate biopsy combined with standard template improves perineural invasion detection.
    Wu CL; Kim M; Wu S; Lin SX; Crotty RK; Harisinghani M; Feldman AS; Dahl DM
    Hum Pathol; 2021 Nov; 117():101-107. PubMed ID: 34461132
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suboptimal Prediction of Clinically Significant Prostate Cancer in Radical Prostatectomy Specimens by mpMRI-Targeted Biopsy.
    Karsiyakali N; Ozgen MB; Ozveren B; Akbal C; Dincer A; Durak H; Turkeri L
    Urology; 2021 Feb; 148():217-223. PubMed ID: 32871139
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Value of 3-Tesla multiparametric magnetic resonance imaging and targeted biopsy for improved risk stratification in patients considered for active surveillance.
    Pessoa RR; Viana PC; Mattedi RL; Guglielmetti GB; Cordeiro MD; Coelho RF; Nahas WC; Srougi M
    BJU Int; 2017 Apr; 119(4):535-542. PubMed ID: 27500389
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis.
    Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM
    Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Magnetic Resonance Imaging/Transrectal Ultrasonography Fusion Prostate Biopsy Significantly Outperforms Systematic 12-Core Biopsy for Prediction of Total Magnetic Resonance Imaging Tumor Volume in Active Surveillance Patients.
    Okoro C; George AK; Siddiqui MM; Rais-Bahrami S; Walton-Diaz A; Shakir NA; Rothwax JT; Raskolnikov D; Stamatakis L; Su D; Turkbey B; Choyke PL; Merino MJ; Parnes HL; Wood BJ; Pinto PA
    J Endourol; 2015 Oct; 29(10):1115-21. PubMed ID: 25897467
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Who Benefits from Multiparametric Magnetic Resonance Imaging After Suspicion of Prostate Cancer?
    Morote J; Celma A; Roche S; de Torres IM; Mast R; Semedey ME; Regis L; Planas J
    Eur Urol Oncol; 2019 Nov; 2(6):664-669. PubMed ID: 31411977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Magnetic resonance imaging-transrectal ultrasound image fusion guidance of prostate biopsies: current status, challenges and future perspectives.
    Boesen L
    Scand J Urol; 2019; 53(2-3):89-96. PubMed ID: 31006323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of Gleason Score 3+4=7 prostate cancer upgrading at radical prostatectomy is significantly reduced by targeted versus standard biopsy.
    De Luca S; Fiori C; Bollito E; Garrou D; Aimar R; Cattaneo G; De Cillis S; Manfredi M; Tota D; Federica M; Passera R; Porpiglia F
    Minerva Urol Nefrol; 2020 Jun; 72(3):360-368. PubMed ID: 31619029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.